Clinical Trial: ECOG-ACRIN EAA173

ECOG-ACRIN EAA173

Status: Open

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

Eligible for screening study DCP 001